Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07641023 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC

Name: Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC — clinical trial record (NCT07641023)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DUO-NK-NSCLC

StatusRecruiting

PhasePhase 1/2

SponsorBeijing Biotech

Started2026-03-02

View on ClinicalTrials.gov ↗

Beijing Biotech

32 trials monitored

See all monitored trials

Lung Cancer

4,033 trials monitored

See 210 trials at risk

Non-Small Cell Lung Cancer (NSCLC)

2,914 trials monitored

See 156 trials at risk

This is a two-part, biomarker-guided Phase 1/2 study evaluating the safety, feasibility, and preliminary anti-tumor activity of off-the-shelf dual-target CAR-NK cells in participants with advanced or metastatic NSCLC whose tumors co-express at least two of the following antigens: Mesothelin (MSLN), EGFR, and HER2/ERBB2. Participants will receive lymphodepleting chemotherapy followed by infusion of the CAR-NK product matched to their tumor antigen profile. A data-driven interim assessment will be used to select the most suitable construct for expansion.

Trial Details

NCT Number	NCT07641023
Lead Sponsor	Beijing Biotech
Conditions	Non-Small Cell Lung Cancer, Advanced/Metastatic
Enrollment	60 participants
Start Date	2026-03-02
Primary Completion	2027-03-14 (estimated)
Study Completion	2028-06-17 (estimated)
Updated on ClinicalTrials.gov	2026-06-11